Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer

Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer

Abstract Purpose Checkpoint inhibition therapy using monoclonal antibodies against programmed cell death protein 1 (PD-1) or its ligand (PD-L1) is now standard management of non-small cell lung cancer (NSCLC). PD-L1 expression is a validated and approved prognostic and predictive biomarker for anti-...

Full description

Bibliographic Details
Main Authors: Daniel Johnathan Hughes, Gitasha Chand, Vicky Goh, Gary J. R. Cook
Format: Article
Language:English
Published: SpringerOpen 2020-12-01
Series:EJNMMI Research
Subjects:
Technetium
SPECT
Non-small cell lung cancer
Immunotherapy
PD-L1
Single-domain antibody (sdAb)
Online Access:https://doi.org/10.1186/s13550-020-00734-x

Internet

https://doi.org/10.1186/s13550-020-00734-x

Similar Items